Newtyn Management, LLC Cytom X Therapeutics, Inc. Transaction History

Newtyn Management, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$1.48 - $2.88 $214,600 - $417,600	-145,000 Reduced 25.44%	425,000 $641,000
Q4 2022 Feb 14, 2023	SELL	$1.19 - $1.91 $273,700 - $439,300	-230,000 Reduced 28.75%	570,000 $912,000
Q3 2022 Nov 14, 2022	SELL	$1.23 - $1.97 $336,282 - $538,598	-273,400 Reduced 25.47%	800,000 $1.16 Million
Q2 2022 Aug 15, 2022	BUY	$1.53 - $2.89 $1.64 Million - $3.1 Million	1,073,400 New	1,073,400 $1.96 Million

50.4M

112K

8.3K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $66M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Newtyn Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Newtyn Management, LLC with notifications on news.